Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

0.00

-0.00 (0.00%)

39 watching

BUY

A Citi Group analyst downgraded the stock so the stock dropped. The consensus earnings forecast since the downgrade has been good and firm. His fair market value is about $60. He feels the stock can do much better.

HOLD

Really like this one when it was around $16. The market had been down on it because of their products looking out and the management in general. A lot of those things have changed. Probably fairly valued now. There is more upside, but wouldn't buy.

BUY

Thinks it bottomed when it got down to the $17/18 area with all the bad news built into the stock. There’s a couple of accounting issues, but doesn’t think they are very serious.

WEAK BUY

Not a stock for the fainthearted. They're doing quite well right now with good partners and good market share. Their problem is generic products that come in and take away market share driving margins down. Have to keep coming out with good products. Trading at a reasonable level. Probably a 15/20% upside for the next couple of years.'

DON'T BUY

The stock has recently managed to run right up against the 200 day moving average trend line and professionals sold. There has been some base building, so there is now a fight between the people who are saying there is a base and those who are saying the stock is fighting the down trend line.

BUY

Long-term chart shows a falling wedge. When you see, this pattern, you can buy into it. It's usually a signal of a long-term trend range.

TOP PICK

His model price is $42, a 56% differential.

SELL

Has always found it expensive and risky. Has had some good news which is already in the stock, so not surprised to see it pull back a little bit.

WAIT

Has ahd a very good move in the last couple of months with fairly good announcements and the stock has had a step up in terms of valuation. Wouldn't chase it here, but would wait for a little bit of weakness in the price.

BUY

Has a model price of $39.55 which is a differential of today's close of 24%. Stiill some room to grow.

WEAK BUY

Because of all the problems this stock has had, he is now selling his holdings. Will buy US companies in the future where there’s a much bigger variety.

SELL

Has had a terrific run with its one dose a day pain killer. Not a fan of the management and the ownership. Prefers others. Not a bad exit point.

WEAK BUY

Has been a big winner on its drug Tramadol. Would be a little cautious at this price.

PAST TOP PICK

(Top Pick Aug 4/05. Up 23%.) Still likes.

DON'T BUY

Recently had a rally from $21 to $28 and is probably ahead of itself at this time. If you own, use a $25 stop/loss.

Showing 346 to 360 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)